It was wildly reported targeting EZH2 can affect systemic immunity, beyond tumor cells.[44] Our study discovered that intervening with EZH2 or USP22 can affect the infiltration of exhausted CD8+ effector T‐cells in the tumor microenvironment, particularly those expressing late‐stage exhausted TIM3+ CD8+T‐cells. The gene discussed is CD8A; the disease is neoplasm.